Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0O6QW
|
||||
| Former ID |
DIB014579
|
||||
| Drug Name |
Manifaxine
|
||||
| Synonyms |
BW-1555U88; GW-320659; GW-320659A
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Major depressive disorder [ICD9: 296.2, 296.3, 710.0; ICD10:F32, F33, M32] | Discontinued in Phase 2 | [1] | ||
| Company |
Glaxo Wellcome plc
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C12H15F2NO2
|
||||
| Canonical SMILES |
[C@]1(c2cc(cc(c2)F)F)(OC[C@H](N[C@H]1C)C)O
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Sodium-dependent noradrenaline transporter | Target Info | Modulator | [2] | |
| Sodium-dependent dopamine transporter | Target Info | Modulator | [2] | ||
| KEGG Pathway | Dopaminergic synapse | ||||
| Parkinson's disease | |||||
| Cocaine addiction | |||||
| Amphetamine addiction | |||||
| Alcoholism | |||||
| PANTHER Pathway | Adrenaline and noradrenaline biosynthesisP00001:Adrenaline and noradrenaline biosynthesis | ||||
| Parkinson disease | |||||
| Dopamine receptor mediated signaling pathway | |||||
| Pathway Interaction Database | Alpha-synuclein signaling | ||||
| Reactome | Na+/Cl- dependent neurotransmitter transportersR-HSA-442660:Na+/Cl- dependent neurotransmitter transporters | ||||
| WikiPathways | Monoamine Transport | ||||
| NRF2 pathway | |||||
| Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compoundsWP727:Monoamine Transport | |||||
| Dopaminergic Neurogenesis | |||||
| Parkinsons Disease Pathway | |||||
| Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds | |||||
| Neurotransmitter Clearance In The Synaptic Cleft | |||||
| References | |||||
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006906) | ||||
| REF 2 | Pharmacogenetics and obesity: common gene variants influence weight loss response of the norepinephrine/dopamine transporter inhibitor GW320659 in obese subjects. Pharmacogenet Genomics. 2005 Dec;15(12):883-9. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.